An interesting (and free) take on the valuation of biotech companies

BVWireIssue #78-1
March 4, 2009

We recently stumbled upon the article, The Art & Science of Valuation in the Biotechnology Marketplace, authored by biotechnology analyst Viren Konde. Although at first glance, Konde’s overview of valuation approaches seems somewhat basic, we highly recommend that analysts with an interest in the biotech area take the time to read the article.

Please let us know if you have any comments about this article or enhancements you would like to see.